English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Neuroendocrine tumors (NETs) are a heterogeneous and complex group of neoplasms that have various biologic, chemical, and physical behaviors, mainly depending on the degree of differentiation and the location (1). The simplest clinical classification is between functioning tumors, for which a specific syndrome related to hypersecretion of peptides, biogenic amines, or hormones is observed, and nonfunctioning, for which no specific symptoms related to tumor production are present (2). Although considered relatively rare entities, NETs are increasing in incidence, with about 70% of them deriving from the gastroenteropancreatic system (1,3).

18F-DOPA and Other Radiopharmaceuticals for Imaging Unknown Primary Neuroendocrine Tumors

¹⁸F-DOPA and Other Radiopharmaceuticals for Imaging Unknown Primary Neuroendocrine Tumors